

We hereby inform that the USFDA inspected the Company's formulations manufacturing facility located at Baddi from 15th to 19th July, 2019. At the end of the inspection, no observation (483) is issued.

Please bring the aforesaid news to the notice of the members of the exchange and the investors at large.